In the SYMPATICO study, in patients with relapsed/refractory MCL, the combination of ibrutinib/venetoclax approximately doubled median PFS compared to ibrutinib plus placebo in both the TP53‐mutated subgroup (20.9 vs. 10.9 months) and the TP53 wild‐type subgroup (46.9 vs. 22.2 months) [34]. The gene discussed is TP53; the disease is mantle cell lymphoma.